KR101451487B1 - 이환형 헤테로환 및 ｃｃｒ２ 수용체 길항제로서의 이의 용도 - Google Patents
이환형 헤테로환 및 ｃｃｒ２ 수용체 길항제로서의 이의 용도 Download PDFInfo
- Publication number
- KR101451487B1 KR101451487B1 KR1020127008883A KR20127008883A KR101451487B1 KR 101451487 B1 KR101451487 B1 KR 101451487B1 KR 1020127008883 A KR1020127008883 A KR 1020127008883A KR 20127008883 A KR20127008883 A KR 20127008883A KR 101451487 B1 KR101451487 B1 KR 101451487B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- hydroxy
- methyl
- oxo
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*C(CO*)(*=C)C(*(C(*)(*)NNC1)C1(C(C)*)N)=O Chemical compound C*C(CO*)(*=C)C(*(C(*)(*)NNC1)C1(C(C)*)N)=O 0.000 description 3
- WQOBJOTWXFAFFJ-YKOWGRMDSA-N C[C@@H](C(N(C(CCCN(CCC1)CC1(F)F)CC1)[C@@H]1C1)=O)N1C(Nc(cc1)cc(Cl)c1Cl)=O Chemical compound C[C@@H](C(N(C(CCCN(CCC1)CC1(F)F)CC1)[C@@H]1C1)=O)N1C(Nc(cc1)cc(Cl)c1Cl)=O WQOBJOTWXFAFFJ-YKOWGRMDSA-N 0.000 description 1
- BBAMMTAITVNSHU-ONYAIIHWSA-N C[C@@H](C(N1C(C2)OC[C@@H]1CC(N(CCC13CC1)C[C@H]3O)=O)=O)N2C(Nc(cc1Cl)ccc1Cl)=O Chemical compound C[C@@H](C(N1C(C2)OC[C@@H]1CC(N(CCC13CC1)C[C@H]3O)=O)=O)N2C(Nc(cc1Cl)ccc1Cl)=O BBAMMTAITVNSHU-ONYAIIHWSA-N 0.000 description 1
- WCDVYJZNVJNVNN-XVSDAANHSA-N C[C@@H](C(N1C(C2)OC[C@@H]1CCCN(CCC13CC1)C[C@H]3O)=O)N2C(Nc1cccc(Cl)c1)=O Chemical compound C[C@@H](C(N1C(C2)OC[C@@H]1CCCN(CCC13CC1)C[C@H]3O)=O)N2C(Nc1cccc(Cl)c1)=O WCDVYJZNVJNVNN-XVSDAANHSA-N 0.000 description 1
- YLYSRBFIACDFCH-FFZOFVMBSA-N C[C@@H](C(N1[C@H](C2)COC[C@@H]1CCN(CCC13CC1)CC3(F)F)=O)N2C(Nc1cc(Cl)ccc1)=O Chemical compound C[C@@H](C(N1[C@H](C2)COC[C@@H]1CCN(CCC13CC1)CC3(F)F)=O)N2C(Nc1cc(Cl)ccc1)=O YLYSRBFIACDFCH-FFZOFVMBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172408.8 | 2009-10-07 | ||
| EP09172408 | 2009-10-07 | ||
| PCT/EP2010/064770 WO2011042399A1 (en) | 2009-10-07 | 2010-10-05 | Bicyclic heterocycles and their use as ccr2 receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120051090A KR20120051090A (ko) | 2012-05-21 |
| KR101451487B1 true KR101451487B1 (ko) | 2014-10-15 |
Family
ID=43105073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127008883A Expired - Fee Related KR101451487B1 (ko) | 2009-10-07 | 2010-10-05 | 이환형 헤테로환 및 ｃｃｒ２ 수용체 길항제로서의 이의 용도 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8471004B2 (enExample) |
| EP (1) | EP2486042B1 (enExample) |
| JP (1) | JP5559336B2 (enExample) |
| KR (1) | KR101451487B1 (enExample) |
| CN (1) | CN102574858B (enExample) |
| AU (1) | AU2010305495A1 (enExample) |
| BR (1) | BR112012008221A2 (enExample) |
| CA (1) | CA2774215A1 (enExample) |
| ES (1) | ES2455266T3 (enExample) |
| IL (1) | IL217965A0 (enExample) |
| IN (1) | IN2012DN00764A (enExample) |
| MX (1) | MX2012002390A (enExample) |
| WO (1) | WO2011042399A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2852160A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| DK3050574T3 (da) | 2015-01-28 | 2020-01-20 | Univ Bordeaux | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom |
| WO2020033791A1 (en) | 2018-08-09 | 2020-02-13 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| CN111423454B (zh) * | 2020-04-24 | 2021-06-22 | 苏州大学 | 哌嗪类化合物及其在制备趋化因子受体ccr2拮抗剂中的应用 |
| CN113979889A (zh) * | 2021-11-09 | 2022-01-28 | 西安康福诺生物科技有限公司 | 一种双官能化聚乙二醇基胺的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3740256A1 (de) | 1987-05-14 | 1988-12-08 | Bayer Ag | Thiazolo-hydantoine |
| WO2002070523A1 (en) * | 2001-03-07 | 2002-09-12 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
| CA2516705A1 (en) * | 2003-02-24 | 2004-09-10 | Merck & Co., Inc. | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity |
| EP1756089B1 (en) * | 2004-05-26 | 2008-10-22 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
| EP1858515A2 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
| KR101176697B1 (ko) * | 2006-04-20 | 2012-08-23 | 에프. 호프만-라 로슈 아게 | 케모카인 수용체의 다이아제판 유도체 조절자 |
| CA2695998A1 (en) | 2007-07-19 | 2009-01-22 | F. Hoffmann-La Roche Ag | Novel heterocyclyl compounds |
| MX2010003621A (es) | 2007-10-01 | 2010-04-14 | Hoffmann La Roche | N-heterociclil biaril carboxamidas como antagonistas del receptor ccr. |
-
2010
- 2010-09-29 US US12/892,968 patent/US8471004B2/en not_active Expired - Fee Related
- 2010-10-05 CN CN201080044805.6A patent/CN102574858B/zh not_active Expired - Fee Related
- 2010-10-05 EP EP10766012.8A patent/EP2486042B1/en not_active Not-in-force
- 2010-10-05 JP JP2012532559A patent/JP5559336B2/ja not_active Expired - Fee Related
- 2010-10-05 MX MX2012002390A patent/MX2012002390A/es active IP Right Grant
- 2010-10-05 CA CA2774215A patent/CA2774215A1/en not_active Abandoned
- 2010-10-05 WO PCT/EP2010/064770 patent/WO2011042399A1/en not_active Ceased
- 2010-10-05 ES ES10766012.8T patent/ES2455266T3/es active Active
- 2010-10-05 AU AU2010305495A patent/AU2010305495A1/en not_active Abandoned
- 2010-10-05 BR BR112012008221A patent/BR112012008221A2/pt not_active IP Right Cessation
- 2010-10-05 KR KR1020127008883A patent/KR101451487B1/ko not_active Expired - Fee Related
- 2010-10-05 IN IN764DEN2012 patent/IN2012DN00764A/en unknown
-
2012
- 2012-02-06 IL IL217965A patent/IL217965A0/en unknown
Non-Patent Citations (2)
| Title |
|---|
| IL Farmaco Edizione. Scientifica, 1973, vol.28(6), pp.463-477 * |
| IL Farmaco Edizione. Scientifica, 1973, vol.28(6), pp.463-477* |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5559336B2 (ja) | 2014-07-23 |
| EP2486042B1 (en) | 2014-01-22 |
| IN2012DN00764A (enExample) | 2015-06-26 |
| ES2455266T3 (es) | 2014-04-15 |
| US20110082294A1 (en) | 2011-04-07 |
| US8471004B2 (en) | 2013-06-25 |
| IL217965A0 (en) | 2012-03-29 |
| AU2010305495A1 (en) | 2012-03-15 |
| MX2012002390A (es) | 2012-04-02 |
| EP2486042A1 (en) | 2012-08-15 |
| BR112012008221A2 (pt) | 2016-03-08 |
| CN102574858B (zh) | 2015-06-24 |
| KR20120051090A (ko) | 2012-05-21 |
| CN102574858A (zh) | 2012-07-11 |
| WO2011042399A1 (en) | 2011-04-14 |
| JP2013506701A (ja) | 2013-02-28 |
| CA2774215A1 (en) | 2011-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8097618B2 (en) | Pyridine derivatives and their use in the treatment of psychotic disorders | |
| US8921368B2 (en) | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | |
| US9428511B2 (en) | Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | |
| US10464909B2 (en) | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | |
| CA2515343C (en) | Antiparasitic terpene alkaloids | |
| CN112585143B (zh) | 作为毒蕈碱m1和/或m4受体的激动剂的桥接化合物 | |
| KR20150036142A (ko) | 신장 외수질 칼륨 채널의 억제제로서 사용하기 위한 스피로 - 융합된 피페리딘 유도체 | |
| JP2009507801A5 (enExample) | ||
| EP2877470B1 (en) | Bicyclic aza-amides for treatment of psychiatric disorders | |
| RU2764980C2 (ru) | Бициклические амины в качестве новых ингибиторов jak-киназы | |
| US20080103178A1 (en) | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | |
| KR20190104600A (ko) | 면역프로테아좀 억제제 | |
| JP2017521399A (ja) | 腎髄質外層カリウムチャンネルの阻害剤 | |
| JP5559336B2 (ja) | 二環式へテロ環及びｃｃｒ２レセプターアンタゴニストとしてのそれらの使用 | |
| CN106488912A (zh) | 肾外髓质钾通道的抑制剂 | |
| EP3255993B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
| ES2782088T3 (es) | Compuestos novedosos | |
| KR20190027877A (ko) | 트립토판 2,3-디옥시제나제(Tryptophan 2,3-dioxygenase)의 억제제 (Inhibitors of Tryptophan 2,3-dioxygenase) | |
| US8633214B2 (en) | Spiro (piperidine-4,2′-pyrrolidine)-1-(3,5-trifluoromethylphenyl) methylcarboxamides as NK1 tachikynin receptor antagonists | |
| WO2024173196A1 (en) | Plasma kallikrein inhibitors | |
| WO2026039170A1 (en) | Il-17a inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20171009 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20171009 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |